Risk factors and medical follow-up of drug users tested for hepatitis C—Can the risk of transmission be reduced?

References

• Serfaty L, Giral P, Elgouzzi MH, Jullien AM, Poupon R. Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology 1993; 17: 183–187
   PubMed Web of Science ®Google Scholar
• Waller T, Holmes R, Hepatitis C. time to wake up. Druglink May–June, 1993; 7–9
   Google Scholar
• Alberti A, Morsica G, Chemello L, Cavaletto D, Noventa F, Pontisso P, Arturo R. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697–698
   PubMed Web of Science ®Google Scholar
• Benhamou JP. Viral hepatitis: chairman's introduction. Gut 1993; 34(suppl 2), IV
   Google Scholar
• American Psychiatric Association. Diagnostic & statistical manual of mental disordersfourth edition Revised. American Psychiatric Association, Washington, DC 1994
   Google Scholar
• Neal KR, Jones DA, Killey D, James V. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK). Epidemiol Infect 1994; 112: 595–601
   PubMed Web of Science ®Google Scholar
• Armitage P, Berry G. Statistical methods in medical research. Blackwell Scientific Publications, Oxford 1994
   Google Scholar
• Brind AM, Serfaty MA, Lawrie A, Watson JP, Johnson S, Gilvarry E, Bassendine MF. Abstract, American Association for the Study of Liver Diseases. Hepatology 1995; 22(4 ii)385A–385A
   Google Scholar
• Ishal, K, et al, Baptista, A, Bianchi, L. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699
   PubMed Web of Science ®Google Scholar
• Majid A, Holmes R, Desselberger U, Simmonds P, McKee TA. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J Med Virol 1995; 46: 48–51
   PubMed Web of Science ®Google Scholar
• Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users; the prevalence of the virus hepatitis C, hepatitis B, human immunodefeciency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655–661
   PubMed Web of Science ®Google Scholar
• Girardi E, Zaccarelli M, Tossini G, Puro V, Narciso P, Visco G. Hepatitis C virus infection in intravenous drug users: prevalence and risk factors. Scand J Infect Dis 1990; 22: 751–752
   PubMed Web of Science ®Google Scholar
• Bell J, Batey RG, Farrell GC, Crewe EB, Cunningham AL, Byth K. Hepatitis C virus in intravenous drug users. Med J Aust 1990; 153: 274–276
   PubMed Web of Science ®Google Scholar
• Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159: 237–241
   PubMed Web of Science ®Google Scholar
• Stimson GV. AIDS and HIV: challenge for British drug services. Br J Addict 1990; 85: 329–339
   PubMedGoogle Scholar
• Donoghoe MC. Syringe exchange: has it worked?. Druglink Jan–Feb, 1991; 8–11
   Google Scholar
• Strasser SI, Wayson KJR, Soon Lee C, Coghlan P, Desmond PV. Risk factors and predictors of outcome in an Australian cohort with hepatitis C infection. Med J Aust 1995; 162: 355–358
   PubMed Web of Science ®Google Scholar
• Botti P, Pistelli A, Gambassi F, Zorn AM, Caramelli L, Peruzzi S, Smorlesi C, Massini E, Mannaioni PF. HBV and HCV infection in IV drug addicts; co-infection with HIV. Arch Virol 1992, suppl 4: 329–332
   PubMedGoogle Scholar
• Watson, JP, et al, Brind, AM, Chapman, CE. Hepatitis C virus: epidemiology and genotypes in the North East of England. Gut 1996; 38: 269–276
   PubMed Web of Science ®Google Scholar
• Yoshioka, K, et al, Kakuma, S, Wakita, S. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293–299, 1992
   PubMed Web of Science ®Google Scholar
• Hino, K, et al, Sainokami, S, Shimoda, K. Genotypes and titres of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299–305
   PubMed Web of Science ®Google Scholar
• Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotypes and response to interferon therapy (Letter). N Engl J Med 1994; 330: 143–143
   PubMed Web of Science ®Google Scholar
• Chief Medical Officer, Home Office, Drugs Branch. Queen Anne's Gate. London, SW1 9AT
   Google Scholar
• Alter, MJ, et al, Margolis, HS, Krawczynski, K. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905
   PubMed Web of Science ®Google Scholar
• Shiell A, Briggs A, Farell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994; 160: 268–272
   PubMed Web of Science ®Google Scholar
• Dushieko GM, Roberts JA. Treatment of chronic type B and C hepatitis with Interferon alpha: an economic appraisal. Hepatology 1995; 22: 1863–1874
   PubMedGoogle Scholar